Biosimilar Sales Up as Insurers Begin Dropping Humira Coverage


Pictured: AbbVie building and pill bottles/Taylor Tieden for BioSpace

AbbVie has so far defended its majority market share among biologics for rheumatoid arthritis despite the loss of exclusivity for its flagship drug Humira (adalimumab). But for the first time since Humira biosimilars appeared last summer, the company’s dominance might be slipping as insurers change coverage policies.

This month, new prescriptions for Humira biosimilars surged 36% after pharmacy benefit manager CVS Caremark removed the AbbVie product from its major formularies in favor of biosimilars for reimbursement. Sandoz’s Hyrimoz accounted for 93% of that growth.

“We attribute much of the success Hyrimoz has had in the last few weeks to the formulary change, and we are building on this,” a Sandoz spokesperson told BioSpace. The spokesperson said the company is negotiating with other health insurers as well. “We are hopeful that the market will…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

ADVERTISEMENT — Advertise With Biotech Networks